Redesign Health, a health-focused venture firm and startup studio, is currently seeking to raise $250 million in funding. Business Insider reports that the New York-based company is looking to secure substantial funding following previous successful fundraising efforts, including a $250 million raise in March 2021 and a $65 million Series C funding round in September 2022.
The details of how the new $250 million raise would be utilized are still unclear as the fundraising efforts are ongoing, and terms could change. Since its establishment in 2018, Redesign Health has launched over 65 healthtech companies. Their unique model combines aspects of a venture capital firm with a startup incubator, resulting in successful ventures such as home health provider MedArrive and weight-loss startup Calibrate.
Investors in Redesign Health include General Catalyst, CVS Health Ventures, and UPMC Enterprises. However, the fundraising landscape for VC firms has evolved significantly since Redesign’s previous fundraising efforts. Some investors have experienced challenges meeting targets, leading to workforce reductions and a pause in new investments.
Within Redesign’s portfolio, some well-funded companies have faced difficulties in securing additional funding. Calibrate, a notable company under Redesign, encountered issues last year with cash burn and customer complaints related to access to weight-loss drugs. Despite these challenges, Redesign Health remains committed to supporting its existing portfolio companies moving forward.
Following a series of funding rounds and workforce adjustments, Redesign’s post-money valuation reached $1.7 billion. Despite recent challenges, the firm is focused on navigating the evolving fundraising landscape and continuing to support its portfolio companies.